| Gene symbol | IL13RA2 | Synonyms | CD213A2, CT19, IL-13R, IL13BP | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq23 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | interleukin 13 receptor subunit alpha 2 | ||||
| GTO ID | GTC2531 |
| Trial ID | NCT04661384 |
| Disease | Leptomeninges Sarcoma | Brain Ependymoma | Medulloblastoma | Glioblastoma |
| Altered gene | IL13RA2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | IL13Ra2 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma |
| Year | 2020 |
| Country | United States |
| Company sponsor | City of Hope Medical Center |
| Other ID(s) | 19497|NCI-2020-06010|19497|P30CA033572 |
| Cohort 1 | |||||||||
|
|||||||||